Advanced Metabolic Reset Protocol

For Indian adults with established metabolic syndrome, insulin resistance, or NAFLD — a comprehensive, physician-designed protocol that goes beyond weight loss to address the full cardiometabolic cluster.

At a Glance

What it targets: The full cardiometabolic cluster — central obesity (particularly visceral fat), insulin resistance, dyslipidaemia, elevated blood pressure, NAFLD/MAFLD, and the systemic inflammation that drives them.

Who it’s for: Adults who meet criteria for metabolic syndrome, have insulin resistance or pre-diabetes, have NAFLD/MAFLD, have Type 2 diabetes with continued cardiometabolic risk despite medication, or who have plateaued on the Tier 1 Metabolic Reset Protocol.

How it works: Physician-supervised combination of ALIV’s cardiometabolic foundation (Tirzepatide microdose + NAD+ microdose + Trim & Tone IV), Tesamorelin for visceral fat, AOD-9604 and MOTS-c in selected cases, plus the lifestyle layer.

What to expect: Visceral fat and inflammatory markers often shift in the early and building phases. Structural metabolic improvements — insulin sensitivity, lipid profile, liver function — follow over the building and sustained phases.

Who This Protocol Is For

Important routing — read this first: This Tier 3 protocol is for established cardiometabolic disease — formal metabolic syndrome, severe insulin resistance, diagnosed NAFLD/MAFLD, T2D with continued risk despite medication, or the high-risk "skinny fat" Indian phenotype. If you don’t yet meet formal diagnostic criteria — weight management focus, no formal diagnosis — the Tier 1 Metabolic Reset Protocol is the right starting point.

India is the global epicentre of metabolic syndrome — a 2020 SR/MA estimated ~30% pooled prevalence across Indian adults. Many of our clients arrive researching type 2 diabetes reversal, metabolic syndrome treatment, insulin resistance treatment, fatty liver treatment, NAFLD, microdose Tirzepatide, or how to reverse visceral fat in India — and want a physician-led integrative approach alongside their diabetologist or cardiologist.

The Indian phenotype matters clinically. South Asian adults accumulate central adiposity at significantly lower BMIs than European populations. 'Skinny fat' is real: normal-BMI Indians can have elevated visceral fat, insulin resistance, and dyslipidaemia. Standard BMI screening misses this picture.

This protocol was built for you if:

• You meet formal criteria for metabolic syndrome — three or more of: central obesity, elevated fasting glucose or diabetes, elevated blood pressure, elevated triglycerides, low HDL
• You have insulin resistance or pre-diabetes and want to reverse the trajectory rather than wait for diabetes
• You’ve been diagnosed with NAFLD/MAFLD — metabolic-dysfunction-associated fatty liver disease
• You have Type 2 diabetes with continued central obesity, dyslipidaemia, or cardiovascular risk despite medication
• You’ve plateaued on the Tier 1 Metabolic Reset Protocol and need a more comprehensive approach
• You’re on a GLP-1 agonist but have hit a plateau with residual visceral fat or metabolic markers
• You’re the ‘skinny fat’ Indian — normal BMI but central fat, poor metabolic markers, and a family history that worries you

How It Works — The ALIV Approach

Metabolic syndrome is not a single disease — it is a disease process with multiple converging drivers: insulin resistance at the cellular level, visceral adipose tissue acting as a hormonally active organ, chronic low-grade inflammation, mitochondrial dysfunction, and behavioural inputs sustaining all of the above. The protocol addresses each.

Layer 1 — The ALIV Cardiometabolic Foundation

Layer 1 combines three interventions that work synergistically: Tirzepatide microdosing, NAD+ microdosing, and the Trim & Tone IV — ALIV's targeted metabolic elixir. Microdosed Tirzepatide gives meaningful glycaemic, weight, and metabolic effects at lower, more tolerable doses than full GLP-1 weight-loss protocols (Indian patients tolerate microdosing markedly better than standard escalation). NAD+ microdosing supports mitochondrial energetics and metabolic flexibility. The Trim & Tone IV delivers L-carnitine and methylated B-complex for fat metabolism support.

Layer 2 — Tesamorelin: Targeted Visceral Fat Reduction

Where visceral fat is a dominant feature, Tesamorelin is added — a growth-hormone-releasing-hormone analogue that selectively reduces visceral adipose tissue, the depot most strongly associated with metabolic and cardiovascular risk. Falutz 2007 NEJM established efficacy. Used selectively in clients with elevated visceral fat by imaging or clinical estimation.

Layer 3 — AOD-9604 and MOTS-c: Lipolysis and Mitochondrial Drivers

AOD-9604 is a growth hormone fragment with selective lipolytic activity, used where targeted fat mobilisation supports the broader protocol. MOTS-c is a mitochondrially-encoded peptide with documented effects on insulin sensitivity in research models. Both are emerging additions; evidence is preliminary and use is selective.

Layer 4 — Diagnostic Precision

Your ALIV physician runs a comprehensive workup beyond standard fasting glucose: HOMA-IR for insulin resistance, full lipid panel including ApoB and Lp(a), hsCRP, HbA1c, liver enzymes and where indicated FibroScan for NAFLD staging, body composition for visceral fat, and red flags requiring cardiology referral: established coronary disease, unstable angina, or significant arrhythmia.

What to Expect

Metabolic syndrome is a multi-year disease process, and reversing or substantially modifying it is a multi-month to multi-year commitment.

Individual outcomes vary based on severity and duration of metabolic disease, genetic factors, adherence to lifestyle and therapy, and existing medications. ALIV does not guarantee specific outcomes.

What’s Involved

Before starting, your ALIV team runs the diagnostic assessment and coordinates with your diabetologist or cardiologist. This protocol is integrative — established cardiovascular and diabetes management is coordinated with, never replaced.

The Lifestyle Layer — Where Metabolic Syndrome Is Won or Lost

No peptide, GLP-1, or IV compensates for the daily inputs that create or sustain metabolic syndrome.

Nutrition targeting insulin resistance: Indian dietary patterns — high refined carbohydrate, frequent snacking, ultra-processed food penetration, low protein density — are metabolically unforgiving. The protocol moves nutrition toward adequate protein intake, whole-food carbohydrates, lower glycaemic load, structured meal timing, and reduced ultra-processed food. Common supplementation: Magnesium, Vitamin D, Omega-3, NAC, NMN, CoQ10, and L-Carnitine — tailored to your assessment.

Structured training — non-negotiable: Resistance training is the most metabolically valuable form of exercise: preserves and builds muscle, improves insulin sensitivity, supports glycaemic control. Aerobic conditioning builds mitochondrial density and cardiovascular capacity — particularly valuable for NAFLD. Daily movement reduces post-prandial glucose excursions.

Sleep, stress, alcohol, ultra-processed food: Sleep deprivation is directly insulinogenic. The Sleep Protocol coordinates where indicated. Chronic stress elevates cortisol, drives visceral fat, worsens insulin resistance. Alcohol and ultra-processed food both drive hepatic fat and quietly undermine every other intervention. Honest conversation is part of the protocol.

Frequently Asked Questions

How is this different from the Tier 1 Metabolic Reset?

Tier 1 addresses metabolic inflexibility and weight — earlier-stage dysfunction. Advanced Metabolic Reset is for established disease: formal metabolic syndrome criteria, insulin resistance, NAFLD, or T2D with continued risk.

Should I start Tirzepatide?

Microdosed Tirzepatide is part of Layer 1 for most clients — meaningful metabolic effects at lower, more tolerable doses than full GLP-1 weight-loss protocols. Whether full-dose Tirzepatide is appropriate depends on your clinical picture.

I’m already on diabetes, BP, and cholesterol medications. Is this protocol for me?

Yes — if anything, you’re a central candidate. The goal is not to replace these medications; it is to modify the underlying disease trajectory so that medication needs may eventually reduce, in coordination with your treating physicians.

Can this reverse fatty liver (NAFLD)?

Meaningful NAFLD improvement is achievable for many clients with comprehensive intervention — weight and visceral fat reduction, insulin sensitisation, exercise, and Tesamorelin have all been shown to improve hepatic steatosis. Advanced fibrotic disease is harder to reverse.

Can type 2 diabetes be reversed?

Type 2 diabetes is potentially reversible for many clients, particularly when caught earlier (shorter duration, lower HbA1c, retained beta-cell function). Achievable: HbA1c moved below the diabetic threshold, medication reduction (specialist-directed), substantial improvement in insulin resistance and visceral fat. Some clients achieve sustained remission for years; long-standing diabetes with significant beta-cell loss is harder to fully reverse. The DiRECT trial demonstrated meaningful remission is achievable. Never stop diabetes medication unilaterally.

Can I reverse metabolic syndrome?

A significant proportion of clients no longer meet formal metabolic syndrome criteria after sustained engagement with comprehensive intervention. Reversal is achievable; maintenance depends on the lifestyle layer holding long-term.

Who should NOT do this protocol?

Type 1 diabetes; active untreated cardiovascular events (acute MI, unstable angina); active malignancy; pregnancy or breastfeeding; clients seeking to bypass appropriate specialist medical management.

Take the Next Step

Metabolic syndrome is not a cosmetic concern — it's the most common pathway to diabetes, cardiovascular disease, and metabolic-dysfunction-associated liver disease in Indian adults.

To find out if the Advanced Metabolic Reset Protocol is right for you, speak with our medical team:

• Pune (Bund Garden): +91 77199 88811
• Mumbai (Khar West): +91 98220 93069

Or book a consultation through alivtherapy.in.

Research References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024

3. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev. 2007;23(2):127-134. PMID: 16752431

4. Krishnamoorthy Y, Rajaa S, Murali S, et al. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS One. 2020;15(10):e0240971. PMC: 7571716

5. Prasad DS, Kabir Z, Dash AK, Das BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: a community study from urban Eastern India. J Cardiovasc Dis Res. 2012;3(3):204-211. DOI: 10.4103/0975-3583.98895

Disclaimer

The information on this page is for educational purposes only and is not intended as medical advice. ALIV therapies are not intended to diagnose, treat, cure, or prevent any disease, including metabolic syndrome, diabetes, NAFLD, or cardiovascular disease. This protocol is integrative supportive care, coordinated with — not a replacement for — specialist endocrinology, cardiology, and hepatology management. Outcomes vary significantly between individuals — ALIV does not guarantee specific outcomes. Tirzepatide is initiated only after physician evaluation; microdosing protocols are off-label and individualised. Tesamorelin is FDA-approved for HIV-associated lipodystrophy; use in other populations is off-label. AOD-9604 and MOTS-c are not FDA-approved and are WADA-banned in competitive athletes. Please consult a qualified healthcare professional before starting any therapy programme.